Home
 > News
print small

Participating Countries:

Algeria

Argentina

Australia

Austria

Belgium

Bosnia and Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

Finland

France

FYR of Macedonia

Germany

Greece

Iceland

Ireland

Israel

Italy

Lithuania

Morocco

Netherlands

New Zealand

Poland

Portugal

Romania

Russian Federation

Serbia

Slovenia

Spain

Sweden

Switzerland

Turkey

Ukraine

United Kingdom

United States

Member area provided by LTFE
COST is supported by the EU Framework Programme Horizon 2020
This website is supported by COST

Advanced planning for electroporation based therapies: electrochemotherapy, nonthermal irreversible electroporation and gene electrotransfer

02/10/2012


Tell your friend  | 

Advanced planning for electroporation

Electrochemotherapy (ECT) is a clinical application of electroporation in which locally applied electric fields are used to create reversible nanoscale defects in cell membranes. The defects increase membrane permeability and allow the increased transport of chemotherapy drugs into the cells.

In new research, ECT treatment planning technology devised by researchers from the University of Ljubljana in Slovenia has been extended for application to other electroporation-based therapies. The technology can now be used for irreversible electroporation (IRE), a tissue ablation method where stronger fields induce permanent membrane defects and cell death, and gene electrotransfer for gene therapy and gene vaccination (GET), where DNA is transported into cells.

To read more, click here.


Project Office

Working groups

Steering Committee

Founding members

DC Rapporteurs

Related sites: